Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N6O.2C3H6O2 |
Molecular Weight | 496.5588 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(O)=O.CCC(O)=O.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=AFGQXWSHYUHHNV-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2C3H6O2/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;2*1-2-3(4)5/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*2H2,1H3,(H,4,5)
Molecular Formula | C3H6O2 |
Molecular Weight | 74.0785 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H20N6O |
Molecular Weight | 348.4017 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4768 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20053484 |
590.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date8.7886083E11 |
|||
Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date9.8867518E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. | 1988 Jun |
|
Determination of whole blood cholinesterase in different animal species using specific substrates. | 2001 Jun |
|
Electron microscopic investigations on stages of dog piroplasms cultured in vitro: Asian isolates of Babesia gibsoni and strains of B. canis from France and Hungary. | 2002 Jan |
|
Residual effect of antibabesial drugs on the live redwater blood vaccines. | 2002 Oct |
|
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. | 2003 Sep 19 |
|
Identification of anti-babesial activity for four ethnoveterinary plants in vitro. | 2005 Jun 10 |
|
Effective imidocarb dipropionate therapy for Babesia shortti in falcons. | 2006 Feb 18 |
|
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats. | 2006 Jul |
|
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures. | 2006 Jun |
|
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis. | 2006 Mar |
|
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb. | 2007 Dec |
|
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs. | 2007 Oct 21 |
|
[Dogs babesiosis--still actually problem]. | 2008 |
|
Canine vector-borne diseases in Brazil. | 2008 Aug 8 |
|
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization. | 2008 Feb 14 |
|
An unusual form of canine babesiosis. | 2008 Mar |
|
Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli). | 2009 Dec |
|
Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state. | 2009 Oct 1 |
|
Canine babesiosis in northern Portugal and molecular characterization of vector-borne co-infections. | 2010 Apr 8 |
|
Haemotropic mycoplasmas: what's their real significance in cats? | 2010 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/imizol.html
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2242963
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:24:44 UTC 2023
by
admin
on
Wed Jul 05 23:24:44 UTC 2023
|
Record UNII |
ZSM1M03SHC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.1156
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
||
|
CFR |
21 CFR 522.1155
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4046604
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
Imidocarb dipropionate
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
1740238
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
ZSM1M03SHC
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
9983292
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
259-791-8
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
C76007
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
55750-06-6
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
300000023751
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
ZSM1M03SHC
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
C031719
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY | |||
|
DBSALT001684
Created by
admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |